Literature DB >> 22239520

The association of HIV viral load with indirect markers of liver injury.

J E Forrester1, M S Rhee, B H McGovern, R K Sterling, T A Knox, N Terrin.   

Abstract

This study assessed the association of HIV RNA with indirect markers of liver injury including FIB-4 index, liver enzymes and platelet counts in a high-risk Hispanic population. The data were derived from a prospective study that included 138 HIV/hepatitis C (HCV)-coinfected and 68 HIV-infected participants without hepatitis C or B co-infection (mono-infected). In unadjusted analyses, detectable HIV viral load (vs undetectable, <400 copies/mL) was associated with a 40% greater odds (OR 1.4, 95% CI: 1.1-1.9, P = 0.016) of FIB-4 > 1.45 in the HIV/HCV-coinfected group and 70% greater odds of FIB-4 > 1.45 (OR 1.7, 95% CI: 1.0-2.8; P = 0.046) in the HIV-mono-infected group. In multivariable analyses, a 1 log(10) increase in HIV RNA was associated with a median increase in FIB-4 of 12% in the HIV/HCV-coinfected group and 11% in the HIV-mono-infected group (P < 0.0001). Among the HIV/HCV-coinfected group, the elevating effect of HIV RNA on FIB-4 was strongest at low CD4 counts (P = 0.0037). Among the HIV-mono-infected group, the association between HIV RNA and FIB-4 was independent of CD4 cell counts. HIV RNA was associated with alterations in both liver enzymes and platelet counts. HIV antiretroviral therapy was not associated with any measure of liver injury examined. This study suggests that HIV may have direct, injurious effects on the liver and that HIV viral load should be considered when these indirect markers are used to assess liver function.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22239520      PMCID: PMC3261587          DOI: 10.1111/j.1365-2893.2011.01529.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  42 in total

1.  Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999.

Authors:  Richard M Selik; Robert H Byers; Mark S Dworkin
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-01       Impact factor: 3.731

2.  Multicenter evaluation of hepatitis C RNA levels among female injection drug users.

Authors:  D L Thomas; J D Rich; P Schuman; D K Smith; J A Astemborski; K R Nolt; R S Klein
Journal:  J Infect Dis       Date:  2001-02-21       Impact factor: 5.226

3.  Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis.

Authors:  C S Graham; L R Baden; E Yu; J M Mrus; J Carnie; T Heeren; M J Koziel
Journal:  Clin Infect Dis       Date:  2001-07-06       Impact factor: 9.079

4.  Dietary intake and body mass index in HIV-positive and HIV-negative drug abusers of Hispanic ethnicity.

Authors:  Janet E Forrester; Katherine L Tucker; Sherwood L Gorbach
Journal:  Public Health Nutr       Date:  2004-10       Impact factor: 4.022

5.  Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism.

Authors:  Neru Munshi; Anuradha Balasubramanian; Margaret Koziel; Ramesh K Ganju; Jerome E Groopman
Journal:  J Infect Dis       Date:  2003-09-30       Impact factor: 5.226

6.  Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.

Authors:  Juan Macías; Victor Castellano; Nicolás Merchante; Rosa B Palacios; José A Mira; Carmen Sáez; José A García-García; Fernando Lozano; Jesús M Gómez-Mateos; Juan A Pineda
Journal:  AIDS       Date:  2004-03-26       Impact factor: 4.177

7.  Increasing incidence of critical liver disease among causes of death in Japanese hemophiliacs with HIV-1.

Authors:  Shinobu Tatsunami; Masashi Taki; Akira Shirahata; Junichi Mimaya; Kaneo Yamada
Journal:  Acta Haematol       Date:  2004       Impact factor: 2.195

8.  Human immunodeficiency virus-induced apoptosis of human hepatocytes via CXCR4.

Authors:  Stacey R Vlahakis; Angelina Villasis-Keever; Timothy S Gomez; Gary D Bren; Carlos V Paya
Journal:  J Infect Dis       Date:  2003-11-18       Impact factor: 5.226

9.  Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection.

Authors:  Nazifa Qurishi; Christina Kreuzberg; Guido Lüchters; Wolfgang Effenberger; Bernd Kupfer; Tilman Sauerbruch; Jürgen K Rockstroh; Ulrich Spengler
Journal:  Lancet       Date:  2003-11-22       Impact factor: 79.321

10.  Hospitalization rates differ by hepatitis C satus in an urban HIV cohort.

Authors:  Kelly A Gebo; Marie Diener-West; Richard D Moore
Journal:  J Acquir Immune Defic Syndr       Date:  2003-10-01       Impact factor: 3.731

View more
  16 in total

1.  Risk factors for liver fibrosis among human immunodeficiency virus monoinfected patients using the FIB4 index in Morocco.

Authors:  Mohamed Tahiri; Mustapha Sodqi; Fatima Ez Zahra Lahdami; Latifa Marih; Hassan Lamdini; Wafaa Hliwa; Ahd Oulad Lahcen; Wafaa Badre; Fouad Haddad; Abdelfetah Chakib; Ahmed Bellabah; Rhimou Alaoui; Kamal Marhoum El Filali
Journal:  World J Hepatol       Date:  2013-10-27

2.  Sex Differences, Cocaine Use, and Liver Fibrosis Among African Americans in the Miami Adult Studies on HIV Cohort.

Authors:  Gustavo Zarini; Sabrina Sales Martinez; Adriana Campa; Kenneth Sherman; Javier Tamargo; Jacqueline Hernandez Boyer; Colby Teeman; Angelique Johnson; Abraham Degarege; Pedro Greer; Qingyun Liu; Yongjun Huang; Raul Mandler; David Choi; Marianna K Baum
Journal:  J Womens Health (Larchmt)       Date:  2020-01-31       Impact factor: 2.681

3.  Association of HIV infection, hepatitis C virus infection, and metabolic factors with liver stiffness measured by transient elastography.

Authors:  M Rami Bailony; Rebecca Scherzer; Gregory Huhn; Michael W Plankey; Marion G Peters; Phyllis C Tien
Journal:  J Infect Dis       Date:  2013-07-30       Impact factor: 5.226

4.  Analysis of HIV quasispecies suggests compartmentalization in the liver.

Authors:  Patricia K Penton; Jason T Blackard
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-25       Impact factor: 2.205

5.  Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras.

Authors:  Marina B Klein; Keri N Althoff; Yuezhou Jing; Bryan Lau; Mari Kitahata; Vincent Lo Re; Gregory D Kirk; Mark Hull; H Nina Kim; Giada Sebastiani; Erica E M Moodie; Michael J Silverberg; Timothy R Sterling; Jennifer E Thorne; Angela Cescon; Sonia Napravnik; Joe Eron; M John Gill; Amy Justice; Marion G Peters; James J Goedert; Angel Mayor; Chloe L Thio; Edward R Cachay; Richard Moore
Journal:  Clin Infect Dis       Date:  2016-08-09       Impact factor: 9.079

6.  Poorly Controlled HIV Infection: An Independent Risk Factor for Liver Fibrosis.

Authors:  H Nina Kim; Robin Nance; Stephen Van Rompaey; Joseph C Delaney; Heidi M Crane; Edward R Cachay; Elvin Geng; Stephen L Boswell; Benigno Rodriguez; Joseph J Eron; Michael Saag; Richard D Moore; Mari M Kitahata
Journal:  J Acquir Immune Defic Syndr       Date:  2016-08-01       Impact factor: 3.731

7.  Interleukin-6 is associated with noninvasive markers of liver fibrosis in HIV-infected patients with alcohol problems.

Authors:  Daniel Fuster; Judith I Tsui; Debbie M Cheng; Emily K Quinn; Kaku A Armah; David Nunes; Matthew S Freiberg; Jeffrey H Samet
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05-17       Impact factor: 2.205

Review 8.  Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.

Authors:  Alexander J Gill; Dennis L Kolson
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

9.  Aspartate aminotransferase-to-platelet ratio index increases significantly 3 years prior to liver-related death in HIV-hepatitis-coinfected men.

Authors:  Jennifer C Price; Eric C Seaberg; Valentina Stosor; Mallory D Witt; Carling D Lellock; Chloe L Thio
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.632

10.  Hepatotoxicity and associated risk factors in HIV-infected patients receiving antiretroviral therapy at Felege Hiwot Referral Hospital, Bahirdar, Ethiopia.

Authors:  Wondemagegn Mulu; Bokretsion Gidey; Ambahun Chernet; Genetu Alem; Bayeh Abera
Journal:  Ethiop J Health Sci       Date:  2013-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.